UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.289-308

2022

Volltextzugriff (PDF)

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9500-9500

2020

Volltextzugriff (PDF)

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9501-9501

2020

Volltextzugriff (PDF)

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e008189

2024

Volltextzugriff (PDF)

Pork for pilgrims: livestock breeding and meat consumption at medieval Banganarti, Nubia

Antiquity, 2020-02, Vol.94 (373), p.164-178

2020

Volltextzugriff (PDF)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

European urology open science (Online), 2022-11, Vol.45, p.12-22

2022

Volltextzugriff (PDF)

Editorial - Quid novi ex Nubia

Études et Travaux, 2019-12 (32), p.7

Żurawski, Bogdan

2019

Volltextzugriff (PDF)

“Oh, My Beloved, Great Bull!” An Interdisciplinary Approach to Cattle as a Marker of Economic and Political Status in Medieval Sub-Saharan Societies

Journal of African archaeology, 2023-06, Vol.21 (1), p.46-62

2023

Volltextzugriff (PDF)

Living with the Past in Modern Sudanese Village. Traditional Pottery Production in the Ad-Dabba Bend of the Nile

Études et Travaux, 2019-12 (32), p.23

2019

Volltextzugriff (PDF)

A systemic literature review of neuroimaging studies in women with breast cancer treated with adjuvant chemotherapy

Contemporary oncology (Poznań, Poland), 2017-01, Vol.1 (1), p.6-15

2017

Volltextzugriff (PDF)

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

The New England journal of medicine, 2023-05, Vol.388 (19), p.1767-1778

2023

Volltextzugriff (PDF)

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2023-03, Vol.401 (10379), p.821-832

2023

Volltextzugriff (PDF)

Banganarti and Selib in 2011/2012 and 2013

Polish archaeology in the Mediterranean, 2016-02, Vol.XXIV (1), p.369-388

Żurawski, Bogdan

2016

Volltextzugriff (PDF)

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

The New England journal of medicine, 2023-11, Vol.389 (22), p.2039-2051

2023

Volltextzugriff (PDF)

DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.1009-1009

2024

Volltextzugriff (PDF)

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Annals of oncology, 2024-01, Vol.35 (1), p.107-117

2024

Volltextzugriff (PDF)

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

European journal of cancer (1990), 2024-11, Vol.211, p.114296, Article 114296

2024

Volltextzugriff (PDF)

Cost-effectiveness analysis of treatment of patients with colorectal cancer with FOLFOX4 and XELOX regimens

Nowotwory, 2017-06, Vol.66 (6), p.470-476

2017

Volltextzugriff (PDF)

CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.18-18

2024

Volltextzugriff (PDF)

Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.LBA360-LBA360

2024

Volltextzugriff (PDF)

Whole BRCA1/2 exome screening in breast cancer tissue: Preliminary study on 45 patients negative in preventive screening analysis in Poland which cover the most common mutations in BRCA1/2 tested in blood

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13615-e13615

2018

Volltextzugriff (PDF)

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

European journal of cancer (1990), 2023-04, Vol.183, p.174-187

2023

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(64)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Pork for pilgrims: livestock breeding and meat consumption at medieval Banganarti, Nubia

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

Editorial - Quid novi ex Nubia

“Oh, My Beloved, Great Bull!” An Interdisciplinary Approach to Cattle as a Marker of Economic and Political Status in Medieval Sub-Saharan Societies

Living with the Past in Modern Sudanese Village. Traditional Pottery Production in the Ad-Dabba Bend of the Nile

A systemic literature review of neuroimaging studies in women with breast cancer treated with adjuvant chemotherapy

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Banganarti and Selib in 2011/2012 and 2013

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial

Cost-effectiveness analysis of treatment of patients with colorectal cancer with FOLFOX4 and XELOX regimens

CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T

Whole BRCA1/2 exome screening in breast cancer tissue: Preliminary study on 45 patients negative in preventive screening analysis in Poland which cover the most common mutations in BRCA1/2 tested in blood

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1

Aktive Filter

Suchergebnisse filtern